{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:28:16Z","timestamp":1777667296154,"version":"3.51.4"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is currently scarce data on the real-world effectiveness and safety of upadacitinib in patients with axial spondyloarthritis (axSpA). This study evaluated clinical outcomes and drug retention rate (DRR) at 6, 12, and 24 months in patients initiating upadacitinib for axSpA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, observational study enrolled consecutive patients with radiographic axSpA (r-axSpA) or non-radiographic axSpA (nr-axSpA) initiating upadacitinib between December 2022 and January 2025\u00a0at 16 Italian centres. The primary endpoints were treatment effectiveness\u2014evaluated using clinimetric indices, including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) \u2014 safety and DRR at 6, 12, and 24 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 203 patients were analysed (48% male; median age at diagnosis 44 years; 22.7% HLA-B27 positive; 71% with nr-axSpA). Sixty-three patients completed the 24-month follow-up. Upadacitinib demonstrated a statistically significant improvement in effectiveness outcomes at 6\u00a0months vs. baseline, which was sustained at 12 and 24 months, regardless of previous biologic therapy lines, axSpA subtype, or sex. Furthermore, DRR was 92%, 80%, and 55% at six, 12, and 24 months, respectively. Forty patients discontinued upadacitinib, including 22 for insufficient effectiveness and two for AEs. Twenty-two patients developed infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Upadacitinib demonstrated a favourable effectiveness profile in the evaluable axSpA population with sustained remission and high treatment retention over a two-year follow-up. Within the limitations inherent to this observational study, the tolerability profile of upadacitinib was generally consistent with that reported in randomized controlled trials, and no new safety signals were identified. Overall, these findings support the effectiveness of Janus kinase inhibitors in the treatment of patients with axSpA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1757110","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:46:05Z","timestamp":1777448765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritis"],"prefix":"10.3389","volume":"17","author":[{"given":"Roberta","family":"Ramonda","sequence":"first","affiliation":[{"name":"Department of Medicine DIMED, Rheumatology Unit, Padova University Hospital","place":["Padova, Italy"]},{"name":"Department of Surgery, Oncology and Gastroenterology (DiSCOG), Padova University Hospital","place":["Padova, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariagrazia","family":"Lorenzin","sequence":"additional","affiliation":[{"name":"Department of Medicine DIMED, Rheumatology Unit, Padova University Hospital","place":["Padova, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Carletto","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rheumatology Unit, AOUI University of Verona","place":["Verona, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Manara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, ASST Gaetano Pini-CTO","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Cozzi","sequence":"additional","affiliation":[{"name":"Department of Medicine DIMED, Rheumatology Unit, Padova University Hospital","place":["Padova, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alen","family":"Zabotti","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rheumatology Division, University of Udine and Azienda Sanitaria Universitaria del Friuli Centrale","place":["Udine, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Foti","sequence":"additional","affiliation":[{"name":"Rheumatology Division, AOU Policlinico \u201cG. Rodolico\u201d San Marco","place":["Catania, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Carriero","sequence":"additional","affiliation":[{"name":"Rheumatology Department of Lucania, San Carlo Hospital of Potenza","place":["Potenza, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariela","family":"Hoxha","sequence":"additional","affiliation":[{"name":"Department of Medicine-DIMED, Thrombotic and Haemorrhagic Diseases Unit, Internal Medicine, Padova University Hospital","place":["Padova, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University","place":["Milan, Italy"]},{"name":"Department of Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Raffeiner","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Central Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU)","place":["Bolzano, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Giollo","sequence":"additional","affiliation":[{"name":"Department of Medicine DIMED, Rheumatology Unit, Padova University Hospital","place":["Padova, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Rheumatology Unit, AOU and University of Cagliari","place":["Monserrato, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of Modena and Reggio Emilia","place":["Reggio Emilia, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Messina","place":["Messina, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rheumatology Unit, AOUI University of Verona","place":["Verona, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Fassio","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rheumatology Unit, AOUI University of Verona","place":["Verona, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Nava","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rheumatology Unit, AOUI University of Verona","place":["Verona, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentino","family":"Paci","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, University Hospital of the Marche Region","place":["Ancona, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Moroncini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, University Hospital of the Marche Region","place":["Ancona, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Buonanno","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Surgery and Neuroscience, Rheumatology Unit, University of Siena, Siena University Hospital","place":["Siena, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Surgery and Neuroscience, Rheumatology Unit, University of Siena, Siena University Hospital","place":["Siena, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele Maria","family":"Luchetti Gentiloni","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, University Hospital of the Marche Region","place":["Ancona, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Gentileschi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Surgery and Neuroscience, Rheumatology Unit, University of Siena, Siena University Hospital","place":["Siena, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"rkae141","DOI":"10.1093\/rap\/rkae141","article-title":"Rationale and concerns for using JAK inhibitors in axial spondyloarthritis","volume":"8","author":"Ahmed","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"key":"B3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11926-017-0654-8","article-title":"Ankylosing spondylitis: HLA-B*27-positive versus HLA-B*27-Negative disease","volume":"19","author":"Akkoc","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2174\/0115733971296457240805064237","article-title":"Efficacy and safety of upadacitinib for axial spondyloarthritis: a systematic review and meta-analysis","volume":"21","author":"Ali","year":"2024","journal-title":"Curr. Rheumatol. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13075-024-03412-8","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-Year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study","volume":"26","author":"Baraliakos","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6632081","DOI":"10.1155\/2022\/6632081","article-title":"Clinical features and prevalence of spondyloarthritis in a cohort of Italian patients presenting with acute nongranulomatous anterior uveitis","volume":"2022","author":"Bolletta","year":"2022","journal-title":"J. Immunol. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40744-024-00671-4","article-title":"Safety profile of upadacitinib up to 5 years in psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis: an integrated analysis of clinical trials","volume":"11","author":"Burmester","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001681","article-title":"Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients","volume":"7","author":"Chimenti","year":"2021","journal-title":"RMD Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1093\/rheumatology\/keab945","article-title":"European bio-naive spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response","volume":"61","author":"Christiansen","year":"2022","journal-title":"Rheumatol. Oxf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13075-024-03396-5","article-title":"Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study","volume":"26","author":"Currado","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e641","DOI":"10.1016\/S2666-7568(22)00214-8","article-title":"Strengthening evidence-based medicine with real-world evidence","volume":"3","author":"Dreyer","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"B7","article-title":"Impact of extreme baseline BASDAI And\/or maastricht AS enthesitis score on treatment response to upadacitinib in patients with axial spondyloarthritis","volume-title":"American college of rheumatology convergence 2023","author":"Dougados","year":"2023"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cpt.2083","article-title":"Randomized controlled trials versus real world evidence: neither magic nor myth","volume":"109","author":"Eichler","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B16","volume-title":"Rinvoq (upadacitinib) summary of product characteristics","year":"2025"},{"key":"B17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40744-024-00734-6","article-title":"Spondyloarthritis and risk of malignancy: a narrative review on a still controversial issue","volume":"12","author":"Favalli","year":"2025","journal-title":"Rheumatol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/acr.25512","article-title":"Sex-related differences in efficacy and safety outcomes in axial spondyloarthritis randomized clinical trials: a systematic literature review and meta-analysis","volume":"77","author":"Gao","year":"2025","journal-title":"Arthritis Care Res. Hob"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3390\/jpm14111105","article-title":"Secukinumab for the treatment of axial spondyloarthritis: long-term real-life data from five Italian referral centers","volume":"14","author":"Gentileschi","year":"2024","journal-title":"J. Pers. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ueg2.12736","article-title":"Gastrointestinal perforations associated with JAK inhibitors: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Goldman","year":"2025","journal-title":"United Eur. Gastroenterol. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1136\/ard-2023-225271","article-title":"Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry","volume":"83","author":"Hernandez-Cruz","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/art.42862","article-title":"Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: a nationwide cohort study","volume":"76","author":"Hoisnard","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"B23","year":"2022"},{"key":"B24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/annrheumdis-2019-216841","article-title":"Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?","volume":"79","author":"Jones","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1093\/rheumatology\/keaf102","article-title":"Interrelationships of disease activity, central sensitization, psychosocial and lifestyle factors in axial spondyloarthritis","volume":"64","author":"Kieskamp","year":"2025","journal-title":"Rheumatol. Oxf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s11926-024-01141-0","article-title":"How to monitor disease activity of axial spondyloarthritis in clinical practice","volume":"26","author":"Kumthekar","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/03009742.2023.2169990","article-title":"Relationship between sex and clinical and imaging features of early axial spondyloarthritis: results from a 48 month follow-up (Italian arm of the SPondyloArthritis caught early (SPACE) study)","volume":"52","author":"Lorenzin","year":"2023","journal-title":"Scand. J. Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4081\/reumatismo.2021.1367","article-title":"The Italian society for rheumatology recommendations for the management of axial spondyloarthritis","volume":"73","author":"Manara","year":"2021","journal-title":"Reumatismo"},{"key":"B29","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.autrev.2009.01.003","article-title":"The interplay between the geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune diseases: a unifying hypothesis","volume":"8","author":"Mathieu","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"B30","article-title":"Real-world effectiveness of upadacitinib on early pain control in patients with axial spondyloarthritis: interim results from the UPSTAND observational study","author":"McCormick","year":"2025","journal-title":"Abstr. POS0891; EULAR"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s10067-025-07360-9","article-title":"Safety of janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022","volume":"44","author":"Mikaeili","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e000524","DOI":"10.1136\/rmdopen-2017-000524","article-title":"Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review","volume":"3","author":"Navarro-Compan","year":"2017","journal-title":"RMD Open"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.semarthrit.2021.07.021","article-title":"The ASAS-OMERACT core domain set for axial spondyloarthritis","volume":"51","author":"Navarro-Compan","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"B35","article-title":"Sustainability of clinical response through 2 years among upadacitinib-treated patients with axial spondylarthritis: data from the SELECT-AXIS 1 and SELECT-AXIS 2 trials","volume-title":"European alliance of associations for rheumatology","author":"Navarro-Comp\u00e1n","year":"2025"},{"key":"B36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/mmt.15.12","article-title":"Epidemiological and genetic factors underlying melanoma development in Italy","volume":"2","author":"Palmieri","year":"2015","journal-title":"Melanoma Manag."},{"key":"B37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/14737167.2022.2032663","article-title":"Analysis of the prevalence of ankylosing spondylitis and treatment patterns and drug utilization among affected patients: an Italian real-world study","volume":"22","author":"Perrone","year":"2022","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ard.2025.06.246","article-title":"POS0891 real-world effectiveness of upadacitinib on early pain control in patients with axial spondyloarthritis: interim results from the upstand observational study","volume":"84","author":"Poddubnyy","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e67729","DOI":"10.7759\/cureus.67729","article-title":"Real-world experience with janus kinase inhibitors in immune-mediated diseases: clinical experience of a university hospital","volume":"16","author":"Ramirez Huaranga","year":"2024","journal-title":"Cureus"},{"key":"B40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1435599","DOI":"10.3389\/fimmu.2024.1435599","article-title":"Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis","volume":"15","author":"Ramonda","year":"2024","journal-title":"Front. Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5152\/eurjrheum.2021.21022","article-title":"Anxiety and depression among patients with axial spondyloarthritis","volume":"9","author":"Reddy","year":"2022","journal-title":"Eur. J. Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41584-020-00552-4","article-title":"Axial spondyloarthritis: concept, construct, classification and implications for therapy","volume":"17","author":"Robinson","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40744-023-00621-6","article-title":"Malignancy in the upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis","volume":"11","author":"Rubbert-Roth","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ejr.2021.12.001","article-title":"Relationship of adherence to treatment with disease activity, physical function, quality of life, treatment satisfaction and beliefs in axial spondyloarthritis patients","volume":"44","author":"Sakr","year":"2022","journal-title":"Egypt. Rheumatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s10067-024-07027-x","article-title":"Upadacitinib for axial spondyloarthritis: a meta-analysis of efficacy and safety","volume":"43","author":"Tang","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13075-024-03441-3","article-title":"Upadacitinib in active non-radiographic axial spondyloarthritis: 2-Year data from the phase 3 SELECT-AXIS 2 study","volume":"27","author":"Van den Bosch","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"Update of the American college of rheumatology\/spondylitis association of america\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13075-019-1995-7","article-title":"Depression in ankylosing spondylitis and the role of disease-related and contextual factors: a cross-sectional study","volume":"21","author":"Webers","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41927-025-00467-1","article-title":"Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis","volume":"9","author":"Yao","year":"2025","journal-title":"BMC Rheumatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1757110\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:46:08Z","timestamp":1777448768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1757110\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":53,"alternative-id":["10.3389\/fphar.2026.1757110"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1757110","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1757110"}}